C. Cremolini

Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progres...

T. Latiano ;

E. Tamburini ;

A. Passardi ;

Sara Lonardi ;

D. Santini ;

H. Lenz ;

A. Zaniboni ;

C. Antoniotti ;

G. Aprile ;

F. Marmorino ;

R. Bordonaro ;

G. Zucchelli ;

G. Fontanini ;

F. Corti ;

M. Korn ;

V. Conca ;

R. Moretto ;

A. Falcone ;

M. Giordano ;

C. Cremolini ;

S. Lonardj ;

C. Ugolini ;

06/30/2020

O-013: Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies.

Access the abstract

Angela Buonadonna ;

Giuliana Ritorto ;

Giacomo Allegrini ;

Carlotta Antoniotti , MD, PhD;

Sara Lonardi ;

F. Marmorino ;

G. Zucchelli ;

B. Borelli ;

R. Moretto ;

A. Falcone ;

Mariaelena Casagrande ;

G. Masi ;

Sabina Murgioni ;

C. Cremolini ;

Emanuela Dell'Aquila ;

A. Zaniboni ;

Gianluca Tomasello ;

G. Aprile ;

Federica Urbano ;

Monica Ronzoni ;

Sara Manglaviti ;

07/31/2019

Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Background Regorafenib is a treatment option for refractory metastatic colorectal cancer (mCRC) patients. The identification of markers to predict or monitor the efficacy of regorafenib r...

F. Marmorino ;

Filippo Pietrantonio ;

A. Boccaccino ;

C. Cremolini ;

M. Antista ;

N. Zaffaroni ;

G. Zucchelli ;

A. Martinetti ;

E. Campi ;

E. Sottotetti ;

B. Borelli ;

F. Corti ;

V. Conca ;

R. Moretto ;

M. Germani ;

A. Falcone ;

M. Giordano ;

C. Antoniotti ;

G. Masi ;

07/02/2021

Background The AtezoTRIBE study demonstrated that the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab prolongs PFS of mCRC patients, but a clinically modest benefit was obse...

Kirk McGregor ;

F. Bergamo ;

S. Leonetti ;

L. Provenzano ;

S. Tamberi ;

M. Ramundo ;

Giampaolo Tortora ;

C. Antoniotti ;

C. Rasola ;

A. Boccaccino ;

D. Ross ;

V. Conca ;

T. Nielsen ;

M. Giordano ;

M. Varga ;

C. Cremolini ;

A. Passardi ;

R. Seitz ;

M. Ambrosini ;

L. Salvatore ;

07/02/2022

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study

AtezoTRIBE (NCT03721653) is a phase II randomized trial in which unresectable mCRC pts were randomized 1:2 to 1st-line FOLFOXIRI/bev [arm A] or FOLFOXIRI/bev/atezo [arm B]. Adding atezo t...

S. Tamberi ;

M. Bensi ;

I. Toma ;

M. De Grandis ;

M. Palermo ;

A. Cappetta ;

Sara Lonardi ;

A. Catteau ;

C. Antoniotti ;

L. Boni ;

F. Marmorino ;

J. Galon ;

V. Conca ;

R. Moretto ;

Filippo Pietrantonio ;

C. Cremolini ;

A. Passardi ;

M. Ambrosini ;

L. Salvatore ;

06/25/2023

Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

Encorafenib plus cetuximab is a standard option in the treatment of BRAFV600E mut mCRC pts pre-treated with at least one systemic therapy. RNF43 is a negative regulator of WNT pathway. A ...

Guglielmo Vetere ;

G. Fontanini ;

Rodrigo De Almeida Toledo ;

F. Bergamo ;

Giovanni Randon , MD;

Simone Oldani ;

Walter Ferrari Bravo ;

Gianmarco Ricagno ;

Paola Vignali ;

Sara Lonardi ;

E. Elez ;

R. Moretto ;